Hiding in Plain Sight: 7-OH Products
The time to act is now. We can and must prevent the next wave of the opioid crisis.
On October 9, 2026, the Drug Enforcement Agency (DEA) issued two new Notices of Intent based on new scientific information and recommendations provided by the U.S. Department of Health and Human Services (HHS).
The updated HHS analysis supports a revised threshold approach for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI) designed to distinguish products containing trace amounts of these substances from formulations that have been intentionally enhanced or concentrated.
- 7-OH and MGPI: HHS recommends that 7-OH and MGPI be subject to Schedule I control when either substance alone, or their combined amount when both are present: Exceeds 1 milligram per gram in solid products or 1 milligram per milliliter in liquid products, or when the ratio of mitragynine to 7-OH, MGPI, or their combined amount is less than 100 to 1. HHS recommends this approach for 7-OH and MGPI to better distinguish products intentionally enhanced or concentrated in these opioid substances from products whose alkaloid composition is more consistent with botanical kratom.
Federal Register Notice: Schedules of Controlled Substances - 7-OH and MGPI - MGM-15 and MGM-16: DEA will reissue the Notice of Intent without changing the current scheduling approach for these substances.
Federal Register Notice: Schedules of Controlled Substances - MGM-15 and MGM-16
On August 26, 2026, DEA temporarily placed MGPI, MGM-15, and MGM-16 into Schedule I. Those controls will remain in effect during the new 30-day Notice of Intent period and until DEA issues a new temporary scheduling order.
Get Help and Report Adverse Events
Report an Adverse Event
If you have a bad reaction to a product containing 7-OH, let the FDA know.
You can report an adverse event by using the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report online.
- Download the form or call 1-800-332-1088 to request a reporting form sent to you in the mail, then complete and return to the address on the form or submit it by fax to 1-800-FDA-0178.
Latest News
FDA Seizes 7-OH Opioids to Protect American Consumers
FDA Takes Step to Restrict Novel Potent Opioid Products Threatening American Consumers
FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine